Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.

Autor: Stroot IAS; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands. Electronic address: i.a.s.stroot@umcg.nl., Bart J; University of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, the Netherlands., Hollema H; University of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, the Netherlands., Jalving M; University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands., Wagner MM; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands., Yigit R; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands., van Doorn HC; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Gynecologic Oncology, Rotterdam, the Netherlands., de Hullu JA; Radboud University Medical Center, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., Gaarenstroom KN; Leiden University Medical Center, Department of Obstetrics and Gynecology, Leiden, the Netherlands., van Beurden M; Antoni van Leeuwenhoek, Department of Gynecology, Amsterdam, the Netherlands., van Lonkhuijzen LRCW; Amsterdam University Medical Center-Center for Gynecological Oncology Amsterdam, Department of Gynecologic Oncology, Amsterdam, the Netherlands., Slangen BFM; Maastricht University Medical Center, Department of Gynecology, Maastricht, the Netherlands., Zweemer RP; University Medical Center Utrecht, Department of Gynecologic Oncology, Utrecht, the Netherlands., Gómez García EB; University Medical Center Maastricht, Department of Clinical Genetics, Maastricht, the Netherlands., Ausems MGEM; University Medical Center Utrecht, Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, Utrecht, the Netherlands., Boere IA; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Medical Oncology, Rotterdam, the Netherlands., van Hest LP; Amsterdam UMC, Location Vrije Universiteit Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands., Duijkers FAM; Amsterdam UMC, University of Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands., van Asperen CJ; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands., Schmidt MK; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands; Netherlands Cancer Institute, Department of Epidemiology, Amsterdam, the Netherlands; Netherlands Cancer Institute, Division of Molecular Pathology, Amsterdam, the Netherlands., Wevers MR; Radboud University Medical Center, Department of Clinical Genetics, Nijmegen, the Netherlands., Ruijs MWG; Netherlands Cancer Institute, Department of Clinical Genetics, Amsterdam, the Netherlands., Devilee P; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands., Collée JM; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Clinical Genetics, Rotterdam, the Netherlands., Hebon Investigators; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Coordinating Center: Netherlands Cancer Institute, Amsterdam, the Netherlands., de Bock GH; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands., Mourits MJE; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2024 Aug; Vol. 187, pp. 198-203. Date of Electronic Publication: 2024 May 24.
DOI: 10.1016/j.ygyno.2024.05.024
Abstrakt: Objective: The aim of this study was to describe the long-term outcome of asymptomatic BRCA1/2 germline pathogenic variant (GPV) carriers with high-grade serous carcinoma (HGSC) in their risk-reducing salpingo-oophorectomy (RRSO) specimen.
Methods: In a previously described cohort of asymptomatic BRCA1/2 GPV carriers derived from the Hereditary Breast and Ovarian cancer in the Netherlands (HEBON) study, women with HGSC at RRSO were identified. Main outcome was ten-year disease-free survival (DFS). Secondary outcomes were time to recurrence, ten-year disease-specific survival (DSS), ten-year overall survival (OS). Patient, disease and treatment characteristics associated with recurrence were described.
Results: The 28 included women with HGSC at RRSO were diagnosed at a median age of 55.3 years (range: 33.5-74.3). After staging, eighteen women had (FIGO) stage I, three stage II and five had stage III disease. Two women did not undergo surgical staging and were classified as unknown stage. After a median follow-up of 13.5 years (range: 9.1-24.7), six women with stage I (33%), one woman with stage II (33%), two women with stage III (40%) and none of the women with unknown stage developed a recurrence. Median time to recurrence was 6.9 years (range: 0.8-9.2 years). Ten-year DFS was 68%, ten-year DSS was 88% and ten-year OS was 82%.
Conclusion: Most asymptomatic BRCA1/2 GPV carriers with HGSC at RRSO were diagnosed at an early stage. Nevertheless, after a median follow-up of 13.5 years, nine of the 28 women with HGSC at RRSO developed a recurrence after a median of 6.9 years.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: